Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2017-2028

2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 CAR-T Therapy in Haematological Malignancy Segment by Type

2.2.1 Allogeneic

2.2.2 Autologous

2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type

2.3.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2017 VS 2022 VS 2028)

2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

2.4 CAR-T Therapy in Haematological Malignancy Segment by Application

2.4.1 Hospitals

2.4.2 Cancer Research Centers

2.4.3 Others

2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application

2.5.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2017 VS 2022 VS 2028)

2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

3 CAR-T Therapy in Haematological Malignancy Market Size by Player

3.1 CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players

3.1.1 Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2020-2022)

3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2020-2022)

3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 CAR-T Therapy in Haematological Malignancy by Regions

4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions (2017-2022)

4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth (2017-2022)

4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth (2017-2022)

4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth (2017-2022)

4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth (2017-2022)

5 Americas

5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2017-2022)

5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022)

5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2017-2022)

6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022)

6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe CAR-T Therapy in Haematological Malignancy by Country (2017-2022)

7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022)

7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Region (2017-2022)

8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022)

8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global CAR-T Therapy in Haematological Malignancy Market Forecast

10.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2023-2028)

10.1.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2023-2028)

10.1.2 Americas CAR-T Therapy in Haematological Malignancy Forecast

10.1.3 APAC CAR-T Therapy in Haematological Malignancy Forecast

10.1.4 Europe CAR-T Therapy in Haematological Malignancy Forecast

10.1.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast

10.2 Americas CAR-T Therapy in Haematological Malignancy Forecast by Country (2023-2028)

10.2.1 United States CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.2 Canada CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.3 Mexico CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.4 Brazil CAR-T Therapy in Haematological Malignancy Market Forecast

10.3 APAC CAR-T Therapy in Haematological Malignancy Forecast by Region (2023-2028)

10.3.1 China CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.2 Japan CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.3 Korea CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.5 India CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.6 Australia CAR-T Therapy in Haematological Malignancy Market Forecast

10.4 Europe CAR-T Therapy in Haematological Malignancy Forecast by Country (2023-2028)

10.4.1 Germany CAR-T Therapy in Haematological Malignancy Market Forecast

10.4.2 France CAR-T Therapy in Haematological Malignancy Market Forecast

10.4.3 UK CAR-T Therapy in Haematological Malignancy Market Forecast

10.4.4 Italy CAR-T Therapy in Haematological Malignancy Market Forecast

10.4.5 Russia CAR-T Therapy in Haematological Malignancy Market Forecast

10.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast by Region (2023-2028)

10.5.1 Egypt CAR-T Therapy in Haematological Malignancy Market Forecast

10.5.2 South Africa CAR-T Therapy in Haematological Malignancy Market Forecast

10.5.3 Israel CAR-T Therapy in Haematological Malignancy Market Forecast

10.5.4 Turkey CAR-T Therapy in Haematological Malignancy Market Forecast

10.5.5 GCC Countries CAR-T Therapy in Haematological Malignancy Market Forecast

10.6 Global CAR-T Therapy in Haematological Malignancy Forecast by Type (2023-2028)

10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 Celgene (Juno Therapeutics)

11.1.1 Celgene (Juno Therapeutics) Company Information

11.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered

11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 Celgene (Juno Therapeutics) Main Business Overview

11.1.5 Celgene (Juno Therapeutics) Latest Developments

11.2 Novartis

11.2.1 Novartis Company Information

11.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Offered

11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Novartis Main Business Overview

11.2.5 Novartis Latest Developments

11.3 Gilead (Kite Pharma)

11.3.1 Gilead (Kite Pharma) Company Information

11.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered

11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.3.4 Gilead (Kite Pharma) Main Business Overview

11.3.5 Gilead (Kite Pharma) Latest Developments

11.4 Pfizer

11.4.1 Pfizer Company Information

11.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Offered

11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.4.4 Pfizer Main Business Overview

11.4.5 Pfizer Latest Developments

11.5 CARsgen Therapeutics

11.5.1 CARsgen Therapeutics Company Information

11.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.5.4 CARsgen Therapeutics Main Business Overview

11.5.5 CARsgen Therapeutics Latest Developments

11.6 Autolus Therapeutics

11.6.1 Autolus Therapeutics Company Information

11.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.6.4 Autolus Therapeutics Main Business Overview

11.6.5 Autolus Therapeutics Latest Developments

11.7 Aurora BioPharma

11.7.1 Aurora BioPharma Company Information

11.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered

11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.7.4 Aurora BioPharma Main Business Overview

11.7.5 Aurora BioPharma Latest Developments

11.8 Sorrento Therapeutics

11.8.1 Sorrento Therapeutics Company Information

11.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.8.4 Sorrento Therapeutics Main Business Overview

11.8.5 Sorrento Therapeutics Latest Developments

11.9 Mustang Bio

11.9.1 Mustang Bio Company Information

11.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered

11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.9.4 Mustang Bio Main Business Overview

11.9.5 Mustang Bio Latest Developments

11.10 Bluebird Bio

11.10.1 Bluebird Bio Company Information

11.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered

11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.10.4 Bluebird Bio Main Business Overview

11.10.5 Bluebird Bio Latest Developments

11.11 Collectis

11.11.1 Collectis Company Information

11.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Offered

11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.11.4 Collectis Main Business Overview

11.11.5 Collectis Latest Developments

11.12 Allogene Therapeutics

11.12.1 Allogene Therapeutics Company Information

11.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.12.4 Allogene Therapeutics Main Business Overview

11.12.5 Allogene Therapeutics Latest Developments

11.13 Celyad

11.13.1 Celyad Company Information

11.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Offered

11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2020-2022)

11.13.4 Celyad Main Business Overview

11.13.5 Celyad Latest Developments

12 Research Findings and Conclusion

Table 1. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)

Table 2. Major Players of Allogeneic

Table 3. Major Players of Autologous

Table 4. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)

Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022) & ($ Millions)

Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

Table 7. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)

Table 8. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022) & ($ Millions)

Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

Table 10. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2020-2022) & ($ Millions)

Table 11. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player (2020-2022)

Table 12. CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

Table 13. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2017-2022 & ($ Millions)

Table 17. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2017-2022)

Table 18. Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2017-2022) & ($ Millions)

Table 19. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2017-2022)

Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022) & ($ Millions)

Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022) & ($ Millions)

Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

Table 24. APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2017-2022) & ($ Millions)

Table 25. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2017-2022)

Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022) & ($ Millions)

Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022) & ($ Millions)

Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

Table 30. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2017-2022) & ($ Millions)

Table 31. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2017-2022)

Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022) & ($ Millions)

Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022) & ($ Millions)

Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

Table 36. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Region (2017-2022) & ($ Millions)

Table 37. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2017-2022)

Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2017-2022) & ($ Millions)

Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2017-2022)

Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2017-2022) & ($ Millions)

Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2017-2022)

Table 42. Key Market Drivers & Growth Opportunities of CAR-T Therapy in Haematological Malignancy

Table 43. Key Market Challenges & Risks of CAR-T Therapy in Haematological Malignancy

Table 44. Key Industry Trends of CAR-T Therapy in Haematological Malignancy

Table 45. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2023-2028) & ($ Millions)

Table 46. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions (2023-2028)

Table 47. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2023-2028) & ($ Millions)

Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2023-2028)

Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2023-2028) & ($ Millions)

Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2023-2028)

Table 51. Celgene (Juno Therapeutics) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 52. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered

Table 53. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 54. Celgene (Juno Therapeutics) Main Business

Table 55. Celgene (Juno Therapeutics) Latest Developments

Table 56. Novartis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 57. Novartis CAR-T Therapy in Haematological Malignancy Product Offered

Table 58. Novartis Main Business

Table 59. Novartis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 60. Novartis Latest Developments

Table 61. Gilead (Kite Pharma) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 62. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered

Table 63. Gilead (Kite Pharma) Main Business

Table 64. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 65. Gilead (Kite Pharma) Latest Developments

Table 66. Pfizer Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 67. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered

Table 68. Pfizer Main Business

Table 69. Pfizer CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 70. Pfizer Latest Developments

Table 71. CARsgen Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 72. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 73. CARsgen Therapeutics Main Business

Table 74. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 75. CARsgen Therapeutics Latest Developments

Table 76. Autolus Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 77. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 78. Autolus Therapeutics Main Business

Table 79. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 80. Autolus Therapeutics Latest Developments

Table 81. Aurora BioPharma Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 82. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered

Table 83. Aurora BioPharma Main Business

Table 84. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 85. Aurora BioPharma Latest Developments

Table 86. Sorrento Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 88. Sorrento Therapeutics Main Business

Table 89. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 90. Sorrento Therapeutics Latest Developments

Table 91. Mustang Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 92. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 93. Mustang Bio Main Business

Table 94. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 95. Mustang Bio Latest Developments

Table 96. Bluebird Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 97. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 98. Bluebird Bio Main Business

Table 99. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 100. Bluebird Bio Latest Developments

Table 101. Collectis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 102. Collectis CAR-T Therapy in Haematological Malignancy Product Offered

Table 103. Collectis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 104. Collectis Main Business

Table 105. Collectis Latest Developments

Table 106. Allogene Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 107. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 108. Allogene Therapeutics Main Business

Table 109. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 110. Allogene Therapeutics Latest Developments

Table 111. Celyad Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 112. Celyad CAR-T Therapy in Haematological Malignancy Product Offered

Table 113. Celyad Main Business

Table 114. Celyad CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 115. Celyad Latest Developments

List of Figures

Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2017-2028 ($ Millions)

Figure 6. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2021

Figure 7. CAR-T Therapy in Haematological Malignancy in Hospitals

Figure 8. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2017-2022) & ($ Millions)

Figure 9. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers

Figure 10. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2017-2022) & ($ Millions)

Figure 11. CAR-T Therapy in Haematological Malignancy in Others

Figure 12. Global CAR-T Therapy in Haematological Malignancy Market: Others (2017-2022) & ($ Millions)

Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2021

Figure 14. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player in 2021

Figure 15. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2017-2022)

Figure 16. Americas CAR-T Therapy in Haematological Malignancy Market Size 2017-2022 ($ Millions)

Figure 17. APAC CAR-T Therapy in Haematological Malignancy Market Size 2017-2022 ($ Millions)

Figure 18. Europe CAR-T Therapy in Haematological Malignancy Market Size 2017-2022 ($ Millions)

Figure 19. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2017-2022 ($ Millions)

Figure 20. Americas CAR-T Therapy in Haematological Malignancy Value Market Share by Country in 2021

Figure 21. Americas CAR-T Therapy in Haematological Malignancy Consumption Market Share by Type in 2021

Figure 22. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2021

Figure 23. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 24. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 25. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 26. Brazil CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region in 2021

Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2021

Figure 29. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 30. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 31. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 32. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 33. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 34. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country in 2021

Figure 36. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2021

Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2021

Figure 38. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 39. France CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 40. UK CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 41. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 42. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region in 2021

Figure 44. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2021

Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2021

Figure 46. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 47. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 48. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 49. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 50. GCC Country CAR-T Therapy in Haematological Malignancy Market Size Growth 2017-2022 ($ Millions)

Figure 51. Americas CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 52. APAC CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 53. Europe CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 54. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 55. United States CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 56. Canada CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 57. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 58. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 59. China CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 60. Japan CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 61. Korea CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 62. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 63. India CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 64. Australia CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 65. Germany CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 66. France CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 67. UK CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 68. Italy CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 69. Russia CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 70. Spain CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 71. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 72. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 73. Israel CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 74. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)

Figure 75. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2023-2028 ($ Millions)